| Product | Developer | Development stage at time of guidance |
|---|
Product | Developer | Development stage at time of guidance |
|---|---|---|
| ABNCoV2 | Bavarian Nordic AS | Clinical phase |
| Ad26.COV2.S | Janssen-Cilag International N.V. | Non-clinical phase |
| Ad5-nCoV vaccine | Cansino Biotech | Clinical phase |
| Ad5-nCoV-IH | Cansino Biotech | Clinical phase |
| Adjuvanted whole virion inactivated vaccine | Sinovac Life Sciences Co | Non-clinical phase |
| ARCT-154 | Arcturus Therapeutics Europe B.V. | Clinical phase |
| CD40.RBDv, CD40.Pan.CoV | LinKinVax | Non-clinical phase |
| ChAdOx1-SARS-CoV-2 | Vaccitech/AstraZeneca | Clinical phase |
| Coronavirus-like particle (COVLP) | Medicago | Non-clinical phase |
| COVI-Liv | Bilthoven Biologicals B.V. | Clinical phase |
| CV0501 | CureVac and GSK | Clinical phase |
| CVnCoV, CV07050101 vaccine | Curevac | Non-clinical phase |
| Dellera, mRNA vaccine | Fondo Ricerca Medica S.r.l. | Clinical phase |
| DNA Plasmid vaccine | Takis S.r.l., Rottapham Biotech | Non-clinical phase |
| FINCoVac 2.0 vaccine | Rokote Laboratories Finland Oy | Non-clinical phase |
| Gam-COVID-Vac | The Gamaleya National Centre of Epidemiology and Microbiology | Clinical phase |
| GBP510 | Sk Bioscience Co. Ltd | Clinical phase |
| GRAd-COV2 | Reithera S.r.l. | Clinical phase |
| GSK&CV SARS-COV-2 vaccine (2nd generation) | GSK and CureVac | Clinical phase |
| Herpes simplex virus vector tetravalent SARS-CoV-2 vaccine | Krystal Bio | Non-clinical phase |
| INO-4800 | Inovio | Clinical phase |
| ISR52 | ISR Vaccine AB | Non-clinical phase |
| LNP-saRNA CoVid19 vaccine | VacEquity Global Health/Imperial College London | Clinical phase |
| LUNAR-COV19 mRNA vaccine | Arcturus Therapeutics | Clinical phase |
| mRNA SARS-CoV-2 vaccine | Biontech | Non-clinical phase |
This information should not be read as an endorsement of any medicine
| Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
|---|
Product | Developer | Therapeutic class/drug type | Development stage at time of guidance |
|---|---|---|---|
| 2-DEOXY-D-GLUCOSE | Dermin Sp. Z.0.0 | Other therapeutic | Non-clinical Phase Clinical phase |
| 4P021 | 4P-Pharma | Antiviral | Non-clinical phase |
| A64-DP | BCN Peptides SA | Immunomodulator | Non-clinical phase |
| ABBV-47D11 | AbbVie | Antiviral | Clinical phase |
| Acalabrutinib | Acerta Pharma BV / AstraZeneca | Immunomodulator | Clinical phase |
| ADG20 | Adagio Therapeutics | Immunomodulator | Clinical phase |
| ALG-097558 | Aligos Belgium BV | Antiviral | Non-clinical phase |
| Anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin | Alliance hyperimmune project (Biotest AG, Bio Products Laboratory, LFB, Octapharma, CSL Behring and Takeda) | Antiviral | Clinical phase |
| APN01 | Apeiron Biologics | Immunomodulator | Clinical phase |
| Apremilast | Amgen Europe BV | Immunomodulator | Clinical phase |
| Aprotinin | Gerencia De Atención Integrada De Ciudad Real | Antiviral | Clinical phase |
| AR-711 | Aridis Pharmaceuticals, Inc. | Antiviral (monoclonal antibody) | Non-clinical phase |
| Arylacenamide | Meletios Therapeutics | Antiviral and immunomodulator | Clinical phase |
| ASUNERCEPT | Apogenix AG | Immunomodulator | Clinical phase |
| AT-527 | Roche | Antiviral | Clinical phase |
| Aviptadil | Relief Therapeutics Holding S.A | Other therapeutic | Clinical phase |
| AZD7442 | AstraZeneca | Antiviral (monoclonal antibody) | Non-clinical phase |
| AZD7518 (AZD3152, AZD3959) | AstraZeneca AB | Antiviral (monoclonal antibody) | Clinical phase |
| Azelastine | Ursapharm | Immunomodulator | Clinical phase |
| Baricitinib | Eli Lilly | Immunomodulator | Clinical phase |
| BC 007 (GS 522 or ARC183) | Berlin Cures | Immunomodulator | Clinical phase |
| Bemcentinib | BergenBio | Antiviral | Clinical phase |
| Bemnifosbuvir hemisulfate | Atea Pharmaceuticals Inc | Antiviral | Clinical phase |
| BI 764198 | Boehringer Ingelheim International GmbH | Other therapeutic | Clinical phase |
| BMS986414 and BMS986413 | Rockefeller University and Bristol Myers Squibb | Antiviral (monoclonal antibody) | Clinical phase |
This information should not be read as an endorsement of any medicine
Reply to the European Ombudsman’s letter concerning transparency and independence of the work of the European Medicines Agency in supporting the development and evaluation of COVID-19 medicines
English (EN) (192.91 KB - PDF)